https://orthotw.com/2026/09/allodirect-announces-pre-seed-round-led-by-m25-to-build-the-ordering-layer-for-tissue-biologicsOrthopedics This Weeken2026-09-25T20:29:00.000ZAlloDirect Announces Pre-Seed Round Led by M25 to Build the Ordering Layer for Tissue & Biologics https://orthotw.com/2026/09/forget-bmi-the-better-measure-is-fat-vs-muscleOrthopedics This Weeken2026-09-25T19:03:00.000ZForget BMI: The Better Measure is Fat vs Muscle https://orthotw.com/2026/09/sacral-fractures-a-survival-signal-that-deserves-a-second-lookOrthopedics This Weeken2026-09-25T18:45:00.000ZSacral Fractures: A Survival Signal That Deserves a Second Look https://orthotw.com/2026/09/si-bone-a-small-cash-milestone-with-larger-implicationsOrthopedics This Weeken2026-09-25T17:46:00.000ZSI-BONE: A Small Cash Milestone With Larger Implications https://orthotw.com/2026/09/johnson-johnson-announces-tremfya-guselkumab-is-the-first-and-only-il-23-inhibitor-to-show-significant-improvement-in-spinal-pain-and-stiffness-in-landmark-axial-psoriatic-arthritis-psa-studyOrthopedics This Weeken2026-09-25T12:01:00.000ZJohnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study https://orthotw.com/2026/09/solenic-medical-appoints-daniel-hawkins-as-chairman-of-the-board-accomplished-medical-device-executive-and-board-leader-brings-deep-industry-experience-as-solenic-enters-its-next-phase-of-clinical-and-strategic-growthOrthopedics This Weeken2026-09-25T11:42:00.000ZSolenic Medical Appoints Daniel Hawkins as Chairman of the Board Accomplished Medical Device Executive and Board Leader Brings Deep Industry Experience as Solenic Enters its Next Phase of Clinical and Strategic Growth